{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:08:07Z","timestamp":1770811687791,"version":"3.50.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1136\/ard.2009.108068","type":"journal-article","created":{"date-parts":[[2010,1,28]],"date-time":"2010-01-28T19:40:11Z","timestamp":1264707611000},"page":"466-467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease"],"prefix":"10.1016","volume":"69","author":[{"given":"L","family":"Naumann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Feist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Natusch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Langen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Krause","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Buttgereit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G-R","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2009.108068_bib1","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1084\/jem.20050640","article-title":"Blocking IL-1 in systemic inflammation.","volume":"201","author":"Dinarello","year":"2005","journal-title":"JEM"},{"key":"10.1136\/ard.2009.108068_bib2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/ncprheum0681","article-title":"Primer: inflammasomes and interleukin 1beta in inflammatory disorders.","volume":"4","author":"Church","year":"2008","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1136\/ard.2009.108068_bib3","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1002\/art.10578","article-title":"Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial.","volume":"46","author":"Nuki","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2009.108068_bib4","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/ard.2004.026617","article-title":"Refractory adult onset Still's disease successfully treated with anakinra.","volume":"64","author":"Vasques Godinho","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2009.108068_bib5","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/art.21061","article-title":"Rapid responses to anakinra in patients with refractory adult-onset Still's disease.","volume":"52","author":"Fitzgerald","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2009.108068_bib6","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/ard.2006.066381","article-title":"Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial.","volume":"66","author":"Kalliolias","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2009.108068_bib7","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2007.076034","article-title":"Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.","volume":"67","author":"Lequerr\u00e9","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2009.108068_bib8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.semarthrit.2007.04.002","article-title":"Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature.","volume":"37","author":"K\u00f6tter","year":"2007","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard.2009.108068_bib9","first-page":"424","article-title":"Preliminary criteria for classification of adult Still's disease.","volume":"19","author":"Yamaguchi","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2009.108068_bib10","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/art.10870","article-title":"Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial.","volume":"48","author":"Fleischmann","year":"2003","journal-title":"Arthritis Rheum"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724196409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724196409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2009.108068","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T01:14:12Z","timestamp":1737249252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724196409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S0003496724196409"],"URL":"https:\/\/doi.org\/10.1136\/ard.2009.108068","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2009.108068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Published by Elsevier Inc. Publishing Group Ltd and European League Against Rheumatism. All rights reserved. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}